Trial Profile

Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 03 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ofatumumab (Primary) ; Rituximab
Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
Focus Registrational; Therapeutic Use
Acronyms HOMER
Sponsors GlaxoSmithKline; GSK; Novartis

Most Recent Events

19 Feb 2017 This trial has been completed in France (end date: 19 Dec 2016).
11 Feb 2017 This trial has been completed in Slovakia (end date: 19 Dec 2016).
08 Feb 2017 This trial has been completed in Belgium (end date: 19 Dec 2016).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com